Crinetics (CRNX) is up 25.7%, or $9.23 to $45.12.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Crinetics rises 21.9%
- Crinetics price target raised to $62 from $58 at Baird
- Buy Rating for Crinetics Pharmaceuticals Driven by FDA Approval and Strategic Market Positioning of Palsonify
- Crinetics Pharmaceuticals Gains FDA Approval for PALSONIFY
- Crinetics price target raised to $143 from $86 at Citizens JMP